Isomorphic Labs raises $5bn Series C for AI drug design
London's Isomorphic Labs closed a $5bn Series C six months after a $2.1bn Series B, enough to fund its drug design engine and the path to human trials.
Also see more funding coverage: /funding/
London, United Kingdom
London-based Isomorphic Labs raised a $5bn Series C on November 17, co-led by Greenoaks and Sequoia Capital, to expand its AI drug design engine and move its cancer and immune programs toward human trials.
A $5bn check six months after $2.1bn
Isomorphic Labs, the Google DeepMind spinout, announced the round on November 17, according to pharmaphorum. Greenoaks and Sequoia Capital co-led. Andreessen Horowitz and other new investors joined, Alphabet made a significant investment, and Fierce Biotech reports that Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund returned. At the November 18 rate of 1.0975 dollars to the euro, our records put the amount at about €4.56bn.
Get the Weekly brief
The week’s rounds, last calls and events, every Monday.
The previous round, a $2.1bn Series B, closed about six months earlier. Total funding now stands above $7.7bn, per pharmaphorum. The new money goes to the company’s drug design engine, called IsoDDE, its preclinical pipeline, and the translational and clinical infrastructure needed to reach patients. Max Jaderberg, Isomorphic’s president, said its machine learning researchers and drug hunters “are routinely solving complex biological problems that have stalled traditional research for decades.” No program timelines were disclosed.
Demis Hassabis, the DeepMind co-founder who also runs Isomorphic, is quoted by pharmaphorum as saying “our drug design engine is generating molecules with unprecedented precision and speed.” The same report lists foundational biology simulation models and a global AI-led bioengineering infrastructure among the targets for the cash. At $5bn, the Series C is about 2.4 times the Series B it follows.
A 2021 spinout with an oncology and immunology pipeline
Isomorphic was founded in 2021 in London, building on DeepMind software such as AlphaFold. Its pipeline targets oncology and immunology across several drug modalities, and the company has not stated its headcount. The full profile, with the round history, sits on its Sesamers startup page.
Seven times UFORCE, 150 times Orakl
Our own database gives the amount a scale. This week’s list includes UFORCE’s $700M Series A for drone production, and the Series C is about seven times that. Orakl Oncology, which raised $34M for virtual-patient drug testing in the same vertical, would fit into it about 150 times. Payhawk’s $280M Series C, announced a day later at Goldman Sachs Alternatives’ lead, is about eighteen times smaller.
A segment analysts size in single-digit billions
MarketsandMarkets, in a November 2024 report, sized AI in drug discovery at $1.86bn in 2024 and projected $6.89bn by 2029, a 29.9% compound annual growth rate. One round at Isomorphic is more than two and a half times the analyst’s 2024 figure for the whole segment. The two numbers measure different things, since the report counts revenue and the round counts capital, so the gap shows how far investor conviction runs ahead of sales today.
Where the lead checks come from
The hard fact is that a London company took the largest round of its life mostly from American money: Sequoia Capital, Greenoaks, Andreessen Horowitz and Thrive Capital, plus Alphabet, GV and CapitalG from the same corporate family, with Temasek in Singapore and MGX in Abu Dhabi alongside. The silver lining is that the UK Sovereign AI Fund is back on the cap table for a second round, which shows public capital willing to stand next to the largest private funds. What to watch is whether European growth investors, such as those tracked on our fundraising data page, start writing checks of this size at home. Imagine if the next $5bn round were led from London.
The first human dosing announcement is the next date to circle. Europe has the lab, the talent and a sovereign backer already in the round, and the opportunity is clear.